Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Monkhorst

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Trauma Surgery & Acute Care Open|December 11, 2020
Relation between intra-abdominal pressure and early intestinal ischemia in ratsSteven G Strang, Ben van der Hoven, Kim Monkhorst, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLCMilou Schuurbiers, Zhongyun Huang, Senglor Saelee, et al.
Plos One|May 15, 2009
The probability to initiate X chromosome inactivation is determined by the X to autosomal ratio and X chromosome specific allelic propertiesKim Monkhorst, Bas de Hoon, Iris Jonkers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung CancerJoris van de Haar, Joanne M Mankor, Karlijn Hummelink, et al.
Plos One|July 31, 2024
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancerKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Cell Reports|May 7, 2020
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized MedicineKrijn K Dijkstra, Kim Monkhorst, Luuk J Schipper, et al.
The Lancet. Oncology|November 27, 2025
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 studyLi-Anne H Douma, Vincent van der Noort, Ferry Lalezari, et al.
The Lancet. Oncology|October 16, 2023
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 studyLi-Anne H Douma, Ferry Lalezari, Vincent van der Noort, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 17, 2025
External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinomaMilou M F Schuurbiers, Freek A van Delft, Hendrik Koffijberg, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Trauma Surgery & Acute Care Open|December 11, 2020
Relation between intra-abdominal pressure and early intestinal ischemia in ratsSteven G Strang, Ben van der Hoven, Kim Monkhorst, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLCMilou Schuurbiers, Zhongyun Huang, Senglor Saelee, et al.
Plos One|May 15, 2009
The probability to initiate X chromosome inactivation is determined by the X to autosomal ratio and X chromosome specific allelic propertiesKim Monkhorst, Bas de Hoon, Iris Jonkers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung CancerJoris van de Haar, Joanne M Mankor, Karlijn Hummelink, et al.
Plos One|July 31, 2024
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancerKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Cell Reports|May 7, 2020
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized MedicineKrijn K Dijkstra, Kim Monkhorst, Luuk J Schipper, et al.
The Lancet. Oncology|November 27, 2025
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 studyLi-Anne H Douma, Vincent van der Noort, Ferry Lalezari, et al.
The Lancet. Oncology|October 16, 2023
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 studyLi-Anne H Douma, Ferry Lalezari, Vincent van der Noort, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 17, 2025
External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinomaMilou M F Schuurbiers, Freek A van Delft, Hendrik Koffijberg, et al.
Pageof 11